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Abstract:
Aptamer technology has shown much promise in cancer
therapeutics for its targeting abilities
In this study, drug-binding aptamers employed to actively load
drugs into liposomes
A series of DNA aptamer sequences specific to doxorubicin
designed, displaying multiple binding sites and various binding
affinities
Optimization of the charge and drug/aptamer ratios resulted in
≥80% encapsulation efficiency of doxorubicin
5
Release and therapeutic efficacy of liposomal doxorubicin
could be controlled by the aptamer's structure
The aptamer exhibiting a specific intermediate affinity is the
best suited to achieve high drug loading while maintaining
efficient drug release and therapeutic activity
This strategy was successfully applied to tobramycin, a
hydrophilic drug suffering from low encapsulation into
liposomes
6
Introduction:
Aptamer technology, although discovered for 25 years, is still
evolving
Aptamers are RNA or DNA sequences generated to
exhibit high affinity and specificity against a broad range of targets
Aptamers recognize their specific targets due to the unique three
dimensional structure
Nucleotides aptamers compared to antibodies:
1) lower immunogenicity
2) higher thermal stability
3) rapid and large scale synthesis
4)lower production costs
7
The pioneering work of Farokhzad et al. first demonstrated the
potential of conjugating an aptamer to the surface of polymeric
nanoparticles for targeting prostate cancers in vivo
Major limitation of nanocarriers: loading sufficient therapeutics
into nanocarriers, while controlling its release rate
Benefits of liposomes:
1) large internal volume for high drug loading
2)prolonged circulation times
3) controlled biodistribution
4) excellent biocompatibility and biodegradability
8
Doxil:
Commercialized liposomes of doxorubicin
Able to reach up to 10,000 molecules of doxorubicin per
liposome
The formulation significantly reduced the cardiotoxicity of
doxorubicin
 The strong entrapment of the drug within the core
significantly reduced its release & its therapeutic efficacy
9
 the loading and release rate of the drug from aptamer-drug
complexes is a function of the sequence and the number of
binding sites
 Disadvantages of aptamer- drug complexes:
1) low stability in the blood
2)limited drug loading capacity
3) some inherent immunogenicity
 Incorporating the drug-aptamer complex into liposomes:
improve specific drug loading and offer a better control over
the release rate to improve the therapeutic efficiency
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Materials & Methods:
Dissociation constants of aptamer-doxorubicin complexes:
 obtained by monitoring the quenching of doxorubicin
fluorescence at various aptamer concentrations
 Fluorescence emission spectrum(λex 485 nm, λem 520–700
nm) was recorded at 37 °C on a Cary Eclipse Fluorescence
spectrophotometer11
Preparation and characterization of liposomes:
All liposome formulations, except Doxil-like, were prepared
using the hydration method
Cationic liposomes: DOTAP, cholesterol and DSPE-PEG2000
(50/48/2 molar ratio)
 “No cationic lipid” formulation: POPC, cholesterol and
DSPEPEG2000 (55/40/5 molar ratio)
Doxil-like liposomes: 55% (DSPC), 40% cholesterol and 5%
DSPEPEG2000
Liposome hydrodynamic diameter and ζ-potential: Malvern
Zetasizer Nano ZS
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Preparation of aptamer-loaded lipoplexes:
Add Aptamer solution to liposomal solution (1:1 v/v) at
N/P ratios (0.5–15)
N: number of amines (molar quantity of
DOTAP)
 P: is the number of phosphorous groups of aptamers
(corresponding to the number of nucleotides)
N/P ratio was optimized for each formulation to
encapsulate>90% of aptamers
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Encapsulation efficiency of aptamers:
Two methods to determine the encapsulation efficiency
of aptamers into cationic liposomes:
1)Indirect method
2)Direct method
 Indirect method:
The residual aptamer concentration in solution was quantified
using fluorescent intercalating probes SYBRGold or SYBRGreen
for Apt-Ctrl-2 or all other aptamers, respectively.
each sample analyzed with a Safire microplate reader (λexc 496
nm, λem 523 nm for both SYBRGreen and SYBRGold).
14
15 Eq (1):
Direct method:
the amount of encapsulated aptamers within the lipoplexes
was quantified directly according to a fluorescent Assay
(496/523 nm (λexc/λem))
16
 t=30 s: lipoplexes added in the cuvette
 t = 100 s: Triton X100 was added to disrupt the
liposomes
 t = 200 s: Final fluorescence was recorded
Stability of lipoplexes:
Encapsulation efficiency of aptamers was measured at 0,
1, 2, 6, 8, 12 and 24 h
 hydrodynamic diameter and polydispersity index were
measured at days 0, 3, 5 and 7.
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Doxorubicin-loaded lipoplexes:
Equal volumes of lipoplexes and doxorubicin solutions were
combined at various doxorubicin/aptamer molar ratios (1:1–
25:1)
N/P ratio and drug/aptamer ratio were optimized for each
formulation
 for Doxil-like liposomes, doxorubicin stock solutionwas added
to pH-gradient liposomes (1:1 v/v)
Doxorubicin encapsulation was determined indirectly by
fluorescence assay(λex 485 nm; λem 585 nm)
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Release kinetics of doxorubicin-loaded lipoplexes:
 doxorubicin-loaded lipoplexes was added to dialysis bags (6–8
kDa MWCO)
Cell viability assay:
HeLa cells
After 24 h, optimized formulation were added to each well, with
final concentrations of doxorubicin ranging from0.01 to 25 μM
per well
 the blank formulation (without doxorubicin)was tested for its
cytotoxicity at its highest concentration
Absorbance was measured at 570 nm and 600 nm
 IC50 was determined
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Tobramycin-loaded lipoplexes:
Tobramycin sulphatewas fluorescently labeled by Cy5.
The binding affinity of Apt-Ctrl-1 for Tobramycin-Cy5 was
measured by fluorescence
Liposomes (DOTAP/Chol/DSPE-PEG2000 50/48/2 molar ratio)
mixed at equal volume (N/P = 3)with the tobramycin/aptamer
solutions or tobramycin solutions without Apt-Ctrl-1 (negative
control)
 Free Tobramycin-Cy5 was quantified in the supernatant by
fluorescence using a Safire microplate reader (λexc 649 nm;
λem 670 nm)
Tobramycin encapsulation efficiency and the final drug/lipid
(D/L) ratio were determined using Eqs. (3) and (4)
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Aptamer design and affinity for doxorubicin:
Results:
Reasonses for selecting Doxorubicin as a model drug:
1) it represents a good example of successful active drug
loading via ammoniumsulphate gradient into liposomes
2) a doxorubicin-binding DNA aptamer has already been
reported
3)binding of doxorubicin to aptamers can be easily
monitored by fluorescence measurements
21
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 emission spectra of doxorubicin (100 nM in 5% dextrose
and 5 mM NaCl) with increasing concentration of Poly-
Doxapt (from top to bottom, 0, 0.001, 0.005, 0.01, 0.05,0.1,
0.25, 0.75, 1, 5, 10, 25 μM).
23 Characteristics of aptamers used in this study and their
affinity constants (KD) for doxorubicin.
24  zeta potential measurements of lipoplexes encapsulating
Doxapt-30:
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Encapsulation efficiency of all aptamerswithin cationic 
lipoplexes
26
 Stability of encapsulated aptamers over 24 h (Doxapt-30 (ratio
N/P = 3) were assayed for their content in aptamers using the
direct and indirect method
27
 Summary of the characteristics for the optimized formulations
28
Encapsulation efficiency of doxorubicin within all aptamer-
loaded lipoplexes
29
Release of doxorubicin at 37 °C in PBS (pH 7.4) from 
optimized formulations of doxorubicin-loaded lipoplexes
30
Cytotoxic activity of doxorubicin in optimized
formulations (see Table 3) on HeLa cells( IC50 values of
doxorubicin in optimized formulations after 48 h.)
31 Tobramycin encapsulation using aptamers
32
Discussion:
 In the passive loading method, the drug dissolved in the aqueous phase
equilibrates with the liposome's internal medium, which limits its
encapsulation efficiency.
 using a gradient method, such as pH or ions, the drug,when present inside
the vesicle core, is converted to an ionic/salt form, which is unable to
diffuse back through the lipid membrane, thus is retained into the
liposome core
 Doxil-like formulation, which exhibited limited release ,high IC50 on
HeLa cells, and even a non-negligible toxicity of the liposomes itself
 Doxapt-28, presenting a similar affinity to Doxapt-30,was not able to
encapsulate N50% of doxorubicin.
 non-specific binding was not detected in the binding affinity
measurements ,it can be explained by the natural affinity of doxorubicin
for nucleic acids or the electrostatic interactions of both cationic drugs
with anionic nucleobases
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 drug binding to the aptamer slowed down the release rate of
the drug in comparison to the free drug, according to its
affinity constant.
Doxapt-30 exhibits a specific affinity for doxorubicin and a
high encapsulation efficiency within cationic lipoplexes,
which resulted in a sustained release profile and an excellent
therapeutic efficiency.
34 Conclusion:
Combining the advantages of aptamer specific properties and
liposomal controlled release enable to achieve tunable
properties according to the structure of the aptamer
 aptamers significantly improved the loading of hydrophilic
tobramycin into liposomes
 adding drug specific sequences to a cancer-targeted aptamer
could lead to better controlled drug delivery systems
 Further improvements are currently focused on the drug/lipid
ratio and the application to larger biomacromolecules
